NCT06363292View on ClinicalTrials.gov

Study to Evaluate the Safety and Tolerability of PRO-231 Versus VIGAMOXI® on the Ocular Surface of Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 30, 2024

Primary Completion Date

May 28, 2024

Study Completion Date

May 28, 2024

Conditions

Ophthalmological Agent ToxicityBacterial Conjunctivitis

Interventions

DRUG

PRO-231

Moxifloxacin 0.5% Ophthalmic solution.

DRUG

VIGAMOXI®

Moxifloxacin 0.5% Ophthalmic solution.

Trial Locations (1)

44610

IIMET Investigación e Innovación en Medicina Traslacional, Guadalajara

All Listed Sponsors

lead

Laboratorios Sophia S.A de C.V.

INDUSTRY

NCT06363292 - Study to Evaluate the Safety and Tolerability of PRO-231 Versus VIGAMOXI® on the Ocular Surface of Healthy Subjects | Biotech Hunter | Biotech Hunter